Aetna Commercial Clinical Program Summary — Medical‑Benefit Drug List and Coverage Guidance
Customize your policy alerts
Sign up for Aetna Policy 4230468-01-03 (07/25) alerts
Get alerted when Policy 4230468-01-03 (07/25) changes without checking for updates manually.
Monitor payer policy activity
Lists medications covered under Aetna's commercial medical benefit with associated therapeutic class, HCPCS codes, precertification requirement, preferred alternatives, and site-of-care indicators; intended for providers submitting or requesting coverage for infused/injected and other medical-benefit drugs.
No material clinical or coverage changes in this revision.
Coverage Criteria and Formulary Placement
General coverage condition
Covered when administrative requirements are met and precertification (when required) is obtained
Clinical eligibility and detailed medical necessity criteria are in separate Clinical Policy Bulletins and the Provider Precertification List.
Formulary placement / benefit assignment
Coverage and benefit placement as listed
Administrative coverage placement; no clinical eligibility rules in this fragment
Formulary placement (per-drug)
Coverage stance is expressed per drug as Preferred, Non-Preferred, Excluded, and as Pharmacy vs Medical benefit where indicated.
No nested clinical criteria provided in these chunks.
This summary is a program-level listing of medical‑benefit medications and administrative attributes. It does not contain the detailed clinical eligibility rules or specific clinical exclusions for any drug. Coverage of a listed medication is contingent on meeting the administrative requirements in this summary and obtaining any required precertification; the specific medical necessity criteria, clinical exclusions, and documentation requirements are contained in the referenced Clinical Policy Bulletins and the Provider Precertification List.
Some biosimilar entries include a usage note indicating they are not appropriate for certain indications. For example, the biosimilar listing for Mvasi carries an explicit notation that it is "not indicated for ocular conditions" in the table, and Avastin is listed elsewhere as the preferred alternative for ophthalmic injectables. Providers should follow those indication notes when selecting an agent for ocular use and consult the underlying clinical policies for formal coverage guidance.
The Combined Benefit Management section shows that formulary placement and benefit channel can differ by product and by benefit. For example, INFLECTRA is listed as Excluded under the pharmacy benefit but Preferred under the medical benefit in the extract; similarly, several colony‑stimulating factor biosimilars and branded agents show mixed Excluded/Preferred/Non‑Preferred statuses depending on whether the listing applies to pharmacy or medical coverage. Verify benefit assignment for each product and member when planning therapy.
Certain products are explicitly marked Excluded in the drug list. Examples in the Combined Benefit Management extract include BRIUMVI and LEMTRADA (MS non‑orals category) and select osteoporosis injectables such as EVENITY and TERIPARATIDE. These exclusion flags indicate the product is not covered under the specified benefit channel shown in the table; check clinical policies and plan documents for any available exceptions or alternative coverage pathways.
This summary does not enumerate specific circumstances labeled as "not medically necessary." Determinations that a service or drug is not medically necessary are made in the payer's detailed Clinical Policy Bulletins and related clinical policies; providers should consult those documents for clinical NMN criteria and appeal processes.
The document states that "Not all health services are covered" and directs readers to plan documents for a complete description of benefits, exclusions, limitations, and conditions of coverage. The program summary itself does not include explicit 'not medically necessary' clinical statements; coverage limits and exclusions are defined in the member's plan documents and in the payer's clinical policies.
HCPCS / J / Q Codes
| J3490 | Myalept; Nulibry; Opuviz; Rivfloza; Strensiq; Skytrofa; many others listed under J3490 |
| J3590 | Myalept; Nulibry; Opuviz; Omisirge; Pavblu; many others listed under J3590 |
| J1602 | SIMPONI ARIA |
Precertification, Prior Authorization, and Provider Requirements
Precertification, Prior Authorization, and Provider Requirements
Many provider-administered drugs listed in this document require precertification or prior authorization before administration. Entries with the field "Precert required = Y" (and the associated HCPCS/Q-codes) indicate a required prior authorization or precertification step. Claims may be denied or delayed if required precertification/prior authorization is not obtained.
- Precertification required for many drugs: Multiple J-, Q-, C-, and S- HCPCS-coded drugs in the list are marked 'Precert required = Y' (e.g., Abecma Q2055; Actemra IV J3262; Adakveo J0791; many others).
- Prior authorization / benefit management indicated: Drugs listed with 'Precert required = Y' are subject to Aetna's clinical drug policies and benefit management (site-of-care requirements, quantity limits, step/therapeutic substitution guidance).
- Documentation for precertification: Providers must submit the required prior authorization request through Aetna's precertification process and include clinical documentation supporting medical necessity, HCPCS/temporary codes, diagnosis, dosing, and any trial/step history as applicable.
- Required documentation and reference guidance: Refer to the Provider Precertification List, Site of Care Policy, and applicable Clinical Policy Bulletins for detailed submission requirements and supporting documentation.
- Precert indication present: Each drug row includes a 'Precert required = Y/N' indicator and HCPCS/temporary billing codes; use these to determine if prior authorization is required prior to claim submission.
- Member coverage verification: Verify member-specific benefits, medical versus pharmacy benefit assignment, and copay/coverage details via the member website or by calling the toll-free number on the member ID card.
- Denial risk from missing precertification or policy compliance: Failure to obtain required precertification/prior authorization or to follow Aetna clinical policies, site-of-care rules, or benefit design may result in claim denial, payment delay, or member financial liability.
- Preferred-alternative / step guidance: Many entries list a 'Preferred Alternative' (including biosimilars or therapeutic alternatives such as Avastin for ophthalmic injectables, Kanjinti/Trazimera for Herceptin, or Monovisc/Orthovisc/Synvisc One for viscosupplements). When a preferred alternative is listed, coverage preference or step requirements may apply.
- Preferred alternatives may impose coverage preference: The Combined Benefit Management Drug List shows pharmacy vs medical benefit status and formulary preference (Preferred, Non-Preferred, Excluded) which can affect coverage and require step therapy or substitution to a preferred agent.
- Formulary preference — no step sequences specified: The document lists formulary preference statuses and benefit assignments but does not specify detailed step-therapy sequences; consult the clinical policy or precertification requirements for step details.
Provider submission and documentation guidance
Operational notes and actions for providers submitting requests:
- Include the HCPCS/Q-code(s) exactly as billed and indicate the 'Precert required' flag shown in the drug list when initiating a prior authorization request.
- Attach supporting clinical records (diagnosis, prior therapies/trials, lab results, and dosing schedule) as required by the applicable Clinical Policy Bulletin.
- Check Site of Care indicators where present (Site of Care = Y) to determine if administration location or alternate site authorization is required.
- When a drug is listed on the Combined Benefit Management Drug List, confirm whether the product is covered under the pharmacy benefit, medical benefit, or is excluded for the member's plan.
- For questions about coverage or to confirm required documentation, contact Aetna or use the provider portal; for member-specific coverage/cost details, direct members to their member website or ID card phone number.
Preferred alternatives and step therapy
Step-therapy and preferred product guidance — what to watch for:
- When a preferred alternative is listed, Aetna may require trial/failure of the preferred agent(s) or documentation of medical rationale for use of the non-preferred product.
- Biosimilar and therapeutic substitution guidance is indicated for many oncology, immunologic, and supportive-care agents (e.g., Zarxio as a preferred alternative to Neupogen; Kanjinti/Trazimera for Herceptin).
- Formulary preference categories (Preferred, Non-Preferred, Excluded) in the Combined Benefit Management Drug List affect coverage and may require prior authorization or step edits; consult the list for benefit assignment details.
Denial risk from missing precertification or policy noncompliance
Denial and billing risk if requirements are not met.
- Claims for HCPCS-coded provider-administered drugs marked 'Precert required = Y' may be denied if authorization is not obtained prior to service.
- Noncompliance with Aetna clinical drug policies, missing documentation, or failure to follow site-of-care or benefit-management requirements can result in claim denials and member liability.
- Prior authorization approvals are specific to the clinical information and codes submitted; billing a different code, dose, or indication than approved can lead to payment adjustments or denials.
Site-of-Care Designations
Biosimilar Preferences and Notes
Table and Flag Definitions
Step Therapy and Preferred Alternatives
| Drug / Category | Preferred Alternative(s) |
|---|---|
| Euflexxa (Viscosupplements) | |
| Monovisc; Orthovisc; Synvisc One | |
| Hyalgan (Viscosupplements) | |
| Monovisc; Orthovisc; Synvisc One | |
| Herceptin (Oncology) | |
| Kanjinti; Trazimera | |
| Infliximab (Immunologic Agents) | |
| Avsola; Inflectra; Renflexis | |
| Eylea / Cimerli (Ophthalmic injectables) | |
| Avastin; Byooviz; Cimerli |
| Drug / Category | Preferred Alternative(s) |
|---|---|
| Supartz FX (Viscosupplements) | |
| Monovisc; Orthovisc; Synvisc One | |
| Synvisc / Synvisc-One (Viscosupplements) | |
| Monovisc; Orthovisc; Synvisc One | |
| Eylea (Ophthalmic medical injectables) | |
| Avastin; Byooviz; Cimerli | |
| Izervay (Ophthalmic medical injectables) | |
| Syfovre |
| Drug / Category | Preferred Alternative(s) |
|---|---|
| Nypozi (G-CSF) | |
| Zarxio | |
| Nyvepria (G-CSF) | |
| Fulphila; Neulasta; Neulasta Onpro | |
| Retacrit (Darbepoetin/Epoetin) | |
| Aranesp; Procrit |
| Drug / Category | Formulary Status (Pharmacy / Medical) |
|---|---|
| AVSOLA (Autoimmune - Infliximab) | |
| Preferred / Preferred | |
| INFLECTRA (Autoimmune - Infliximab) | |
| Excluded / Preferred | |
| REMICADE (Autoimmune - Infliximab) | |
| Preferred / Pharmacy coverage only | |
| BRIUMVI (Multiple Sclerosis Non-Orals) | |
| Excluded / Non-Preferred | |
| KESIMPTA (Multiple Sclerosis Non-Orals) | |
| Preferred / Pharmacy coverage only | |
| SIMPONI ARIA (Autoimmune Infused Other) | |
| Medical coverage only / Preferred | |
| FULPHILA (Colony Stimulating Factors) | |
| Preferred / Non-Preferred | |
| NEULASTA (Colony Stimulating Factors) | |
| Excluded (Pharmacy) / Non-Preferred (Medical) | |
| EVENITY (Osteoporosis Injectable) | |
| Excluded (Pharmacy coverage only) |
| Note | Implication |
|---|---|
| Formulary statuses are listed as Preferred, Non-Preferred, or Excluded across pharmacy and medical benefit channels. | |
| These listings indicate relative coverage preference but the document does not define step therapy sequences. | |
| Some drugs are designated 'Pharmacy coverage only' or 'Medical coverage only' (e.g., SIMPONI ARIA = Medical coverage only). | |
| Benefit-specific preferences may differ by drug (e.g., INFLECTRA Excluded on pharmacy but Preferred on medical). |
Policy Background and Scope
This is a program‑level formulary summary that maps a large set of medical‑benefit medications to their therapeutic classes, HCPCS/J/Q billing codes, precertification requirement (Y/N), listed preferred alternatives, and site‑of‑care flags. It supplements but does not replace detailed clinical drug policies: providers must follow the Provider Precertification List, Site of Care Policy, and Clinical Policy Bulletins for documentation, prior authorization, and medical necessity determinations.
Revision History
Combined Benefit Management listing for infliximab biosimilars updated: Avsola (Q5121) listed as Preferred for both benefits; Inflectra (Q5103) listed as Excluded on pharmacy but Preferred on medical; Infliximab/Remicade (J1745) listed as Preferred with pharmacy coverage only; Renflexis (Q5104) listed as Excluded on pharmacy but Preferred on medical.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.